Maurício Ribeiro, MD
@mauriciofribei1
Medical Oncologist. Assistant Member at @moffittnews @usfhealthmed. Former Fellow in #sarcoma and #melanoma at @pmcancercentre @uoft - my tweets = my views
ID:1048958038676258819
07-10-2018 15:27:39
500 Tweets
927 Followers
1,0K Following
The registrational enabling Spearhead-1 study shows that afami-cel, an engineered T cell targeting MAGEA4, has promising efficacy in synovial sarcoma and MRCLS paving the way for T cell therapy in solid tumors. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Sarcoma Service at Memorial Sloan Kettering
sciencedirect.com/science/articl…
3 or 6 years of adjuvant imatinib in #GIST ?
🔹better DFS for 6 years
🔹need mature OS data
🚨NOT ready for change of clinical praktyce
Great discussion by César Serrano García
#ESMOSarcomaAndRareCancers24 #ESMOAmbassadors ESMO - Eur. Oncology
Lifileucel (TIL cell therapy from Iovance Biotherapeutics) is now FDA approved for advanced PD-1 refractory melanoma!!! The melanoma community is so grateful to the patients, caregivers, and clinicians who have made the clinical trials of this therapy possible and got lifileucel to approval.…
Dr. Mauricio Ribeiro is a #sarcoma Medical Oncologist Moffitt Cancer Center interested in early-phase trials and management of desmoid tumors/ soft tissue sarcomas, especially radiation-associated and vascular sarcomas. Go give him a follow Maurício Ribeiro, MD! #FollowFriday